{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:35:44Z","timestamp":1762252544152},"reference-count":49,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.3892\/mmr.2017.6636","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T09:01:07Z","timestamp":1495789267000},"page":"523-532","source":"Crossref","is-referenced-by-count":9,"title":["Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia"],"prefix":"10.3892","volume":"16","author":[{"given":"Xiao","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"key20180108004916_b1-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer Statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"key20180108004916_b2-mmr-16-01-0523","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren","year":"2009","journal-title":"Biologics"},{"key":"key20180108004916_b3-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic Myeloid Leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"key20180108004916_b4-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Target Oncol"},{"key":"key20180108004916_b5-mmr-16-01-0523","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"142","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"key20180108004916_b6-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"key20180108004916_b7-mmr-16-01-0523","first-page":"1838","volume":"82","author":"Mandanas","year":"1993","journal-title":"Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells"},{"key":"key20180108004916_b8-mmr-16-01-0523","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1","volume":"22","author":"Okuda","year":"1994","journal-title":"Exp Hematol"},{"key":"key20180108004916_b9-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108004916_b10-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"key20180108004916_b11-mmr-16-01-0523","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"key20180108004916_b12-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/07357900802653498","article-title":"t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis","volume":"27","author":"Tan","year":"2009","journal-title":"Cancer Invest"},{"key":"key20180108004916_b13-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: Diagnosis and treatment","volume":"81","author":"Quint\u00e1s-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"key20180108004916_b14-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"key20180108004916_b15-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00001622-200403000-00002","article-title":"Treatment options for chronic myeloid leukemia: Imatinib versus interferon versus allogeneic transplant","volume":"16","author":"Angstreich","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"key20180108004916_b16-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia","volume":"15","author":"Gora-Tybor","year":"2008","journal-title":"Curr Med Chem"},{"key":"key20180108004916_b17-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180108004916_b18-mmr-16-01-0523","article-title":"gcrma: Background adjustment using sequence information","author":"Wu","journal-title":"R package"},{"key":"key20180108004916_b19-mmr-16-01-0523","article-title":"genefilter: genefilter: Methods for filtering genes from microarray experiments","author":"Gentleman","journal-title":"R package"},{"key":"key20180108004916_b20-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","article-title":"Limma: Linear models for microarray data","volume-title":"Bioinformatics and Computational Biology Solutions Using R and Bioconductor","author":"Smyth","year":"2005"},{"key":"key20180108004916_b21-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/10343","article-title":"Systematic determination of genetic network architecture","volume":"22","author":"Tavazoie","year":"1999","journal-title":"Nat Genet"},{"key":"key20180108004916_b22-mmr-16-01-0523","article-title":"GO.db: A set of annotation maps describing the entire Gene Ontology","author":"Carlson","journal-title":"R package"},{"key":"key20180108004916_b23-mmr-16-01-0523","article-title":"KEGG.db: A set of annotation maps for KEGG","author":"Carlson","journal-title":"R package"},{"key":"key20180108004916_b24-mmr-16-01-0523","article-title":"KEGGREST: Client-side REST access to KEGG","author":"Tenenbaum","journal-title":"R package"},{"key":"key20180108004916_b25-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"D767","DOI":"10.1093\/nar\/gkn892","article-title":"Human protein reference database-2009 update","volume":"37","author":"Prasad","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20180108004916_b26-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gks1158","article-title":"The BioGRID interaction database: 2013 update","volume":"41","author":"Chatr-aryamontri","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"key20180108004916_b27-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"D651","DOI":"10.1093\/nar\/gkn870","article-title":"PIPs: Human protein-protein interaction prediction database","volume":"37","author":"McDowall","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20180108004916_b28-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/bioinformatics\/btq675","article-title":"Cytoscape 2.8: New features for data integration and network visualization","volume":"27","author":"Smoot","year":"2011","journal-title":"Bioinformatics"},{"key":"key20180108004916_b29-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180108004916_b30-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1381612805666230110214512","article-title":"An overview of cyclophosphamide development and clinical applications","volume":"5","author":"Colvin","year":"1999","journal-title":"Curr Pharm Des"},{"key":"key20180108004916_b31-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4615-1173-1_8","article-title":"Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s)","volume-title":"Clinically Relevant Resistance in Cancer Chemotherapy","author":"Sl\u00e1dek","year":"2002"},{"key":"key20180108004916_b32-mmr-16-01-0523","first-page":"65","article-title":"The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide","volume":"290","author":"Russo","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"key20180108004916_b33-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-006-0233-6","article-title":"RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide","volume":"59","author":"Moreb","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108004916_b34-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2007.03.018","article-title":"Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes","volume":"255","author":"Plebuch","year":"2007","journal-title":"Cancer Lett"},{"key":"key20180108004916_b35-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00450-6","article-title":"Midkine and pleiotrophin in neural development and cancer","volume":"204","author":"Kadomatsu","year":"2004","journal-title":"Cancer Lett"},{"key":"key20180108004916_b36-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2006.03.017","article-title":"Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance","volume":"247","author":"Kang","year":"2007","journal-title":"Cancer Lett"},{"key":"key20180108004916_b37-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s13277-012-0406-3","article-title":"Midkine confers Adriamycin resistance in human gastric cancer cells","volume":"33","author":"Xu","year":"2012","journal-title":"Tumor Biol"},{"key":"key20180108004916_b38-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10555-011-9338-4","article-title":"S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence","volume":"31","author":"Mishra","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"key20180108004916_b39-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1158\/0008-5472.CAN-07-0440","article-title":"S100A4 Contributes to the suppression of BNIP3 expression, chemoresistance and inhibition of apoptosis in pancreatic cancer","volume":"67","author":"Mahon","year":"2007","journal-title":"Cancer Res"},{"key":"key20180108004916_b40-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/pr400457u","article-title":"TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells","volume":"12","author":"Hekmat","year":"2013","journal-title":"J Proteome Res"},{"key":"key20180108004916_b41-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11882-008-0004-z","article-title":"A current understanding of Fc epsilon RI-dependent mast cell activation","volume":"8","author":"Rivera","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"key20180108004916_b42-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer-new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108004916_b43-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"e97243","DOI":"10.1371\/journal.pone.0097243","article-title":"BCR-ABL Affects STAT5A and STAT5B differentially","volume":"9","author":"Schaller-Sch\u00f6nitz","year":"2014","journal-title":"PLoS One"},{"key":"key20180108004916_b44-mmr-16-01-0523","first-page":"1215","article-title":"STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells","volume":"5","author":"Hong","year":"2012","journal-title":"Mol Med Rep"},{"key":"key20180108004916_b45-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.24879","article-title":"Fyn: A novel molecular target in cancer","volume":"116","author":"Saito","year":"2010","journal-title":"Cancer"},{"key":"key20180108004916_b46-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/onc.2014.138","article-title":"Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy","volume":"34","author":"Elias","year":"2015","journal-title":"Oncogene"},{"key":"key20180108004916_b47-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Fenouille","year":"2010","journal-title":"Cancer Res"},{"key":"key20180108004916_b48-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.drudis.2010.05.001","article-title":"Spleen tyrosine kinases: Biology, therapeutic targets and drugs","volume":"15","author":"Riccaboni","year":"2010","journal-title":"Drug Discov Today"},{"key":"key20180108004916_b49-mmr-16-01-0523","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:16:21Z","timestamp":1692818181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.6636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,26]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.3892\/mmr.2017.6636"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.6636","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}